AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed
Unknown subjects: Therapy selection for psoriasis
The article discusses how the selection of treatment options for psoriasis has greatly improved, reflecting the growing variety of available therapies.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This evolution in treatment options allows for individualized care based on patient characteristics such as comorbid conditions and previous treatment responses, enhancing personal healthcare.
What this does not prove
The article does not provide specific results for any treatments, focusing only on therapy selection rather than efficacy or clinical outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-19
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidencePsoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents. ↗DOI: 10.1016/j.jaad.2026.09.132
Supporting passages (3)
findingsSelection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences.
publication datePublication date: 2026-10-19
limitationsTitle: Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.